Modelling A.I. in Economics

ARWR Stock: Undervalued Gem or Risk Worth Avoiding?

Outlook: ARWR Arrowhead Pharmaceuticals Inc. is assigned short-term Ba2 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Reinforcement Machine Learning (ML)
Hypothesis Testing : Linear Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Arrowhead anticipated to deliver encouraging clinical trial data for its liver disease therapies, potentially driving stock price increase.
  • Strong advancements in RNA interference technology expected to broaden Arrowhead's therapeutic pipeline, attracting investor interest.
  • Possible strategic partnerships or collaborations with pharmaceutical giants could accelerate drug development and boost stock value.
  • Continued expansion into new therapeutic areas beyond liver diseases might enhance Arrowhead's market opportunities and investor confidence.
  • If Arrowhead successfully navigates regulatory hurdles and gains drug approvals, it could lead to substantial revenue growth and stock appreciation.


Arrowhead Pharmaceuticals Inc. (ARWR) is a biopharmaceutical company focused on developing medicines that treat genetic diseases and other conditions. ARWR utilizes technology to create RNA interference (RNAi) therapeutics, which target specific genes and prevent their expression. This approach allows ARWR to target the root cause of genetic diseases, thereby potentially offering a curative treatment option. The company's lead product candidate, ARO-AAT, is in Phase 3 clinical trials for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD). ARWR also has a robust pipeline of other RNAi therapeutics in various stages of development for diseases such as hepatitis B virus (HBV), amyotrophic lateral sclerosis (ALS), and cancer.

ARWR stock has been on a steady upward trajectory in recent years, reflecting the promise of its RNAi technology and the potential of its pipeline. In 2021, the stock price rose significantly after the company announced positive Phase 2 data for ARO-AAT and initiated a Phase 3 trial. Additionally, ARWR's collaboration with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the development and commercialization of ARO-HBV further boosted investor confidence. As of March 2023, ARWR stock is trading at around $45 per share, indicating a market capitalization of approximately $5.5 billion.

Graph 20

ARWR Stock Price Prediction Model

To construct a robust machine learning model for predicting ARWR stock prices, we must first gather and preprocess historical data. This dataset should encompass a wide range of variables that may influence stock performance, including economic indicators, market trends, company financials, and analyst ratings. Once collected, the data must be cleaned and transformed to ensure consistency and compatibility with our chosen machine learning algorithms.

In selecting a suitable algorithm, we consider several factors, including the complexity of the data, the desired level of accuracy, and the computational resources available. Popular choices for stock prediction include linear regression, support vector machines, decision trees, and neural networks. We may employ ensemble methods, which combine multiple algorithms, to enhance the overall performance of our model.

To evaluate the effectiveness of our model, we divide the preprocessed data into training and testing sets. The training set is used to train the model, while the testing set is reserved for assessing its performance. We utilize metrics such as mean absolute error, mean squared error, and the R-squared coefficient to quantify the accuracy of our predictions. Additionally, we perform cross-validation to ensure that our model is not overly sensitive to the specific划分 of the data into training and testing sets.

ML Model Testing

F(Linear Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Reinforcement Machine Learning (ML))3,4,5 X S(n):→ 8 Weeks r s rs

n:Time series to forecast

p:Price signals of ARWR stock

j:Nash equilibria (Neural Network)

k:Dominated move of ARWR stock holders

a:Best response for ARWR target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ARWR Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

ARWR Arrowhead Pharmaceuticals Inc. Financial Analysis*

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that treat intractable diseases by silencing the genes that cause them. The company has a strong financial foundation and is well-positioned for continued growth in the coming years.

Arrowhead's revenue is primarily driven by collaboration agreements and research and development (R&D) services. In 2022, the company reported total revenue of $226.3 million, a significant increase from $112.1 million in 2021. This growth is expected to continue in the future as the company advances its pipeline of product candidates and expands its collaboration agreements.

Arrowhead's expenses are primarily related to R&D activities, which are essential for the development of its product candidates. The company's R&D expenses increased from $119.6 million in 2021 to $168.1 million in 2022, reflecting the company's commitment to advancing its pipeline. Arrowhead's general and administrative expenses also increased from $26.4 million in 2021 to $37.3 million in 2022.

Arrowhead's financial outlook is positive, with the company expecting continued revenue growth and a potential for profitability in the future. The company's strong pipeline of product candidates, including several that are in late-stage development, is expected to drive future revenue growth. Additionally, Arrowhead's collaboration agreements with major pharmaceutical companies provide a steady stream of revenue and access to resources that can help accelerate the development of its product candidates. As the company continues to advance its pipeline and expand its collaborations, it is well-positioned for continued financial success in the coming years.

Rating Short-Term Long-Term Senior
Income StatementB3B2
Balance SheetCaa2B1
Leverage RatiosBaa2Ba2
Cash FlowBaa2Baa2
Rates of Return and ProfitabilityBaa2Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Arrowhead Pharmaceuticals Inc. Market Overview and Competitive Landscape

Arrowhead Pharmaceuticals, a clinical-stage biopharmaceutical company, is focused on developing medicines that treat intractable diseases by silencing the genes that cause them. Utilizing its proprietary Targeted RNAi Molecule (TRiM) platform, Arrowhead designs small interfering RNA (siRNA) molecules aimed at silencing disease-causing genes in a precise and durable manner. The company's pipeline encompasses various therapeutic areas, including cardiovascular, respiratory, liver, and neurological diseases. Arrowhead's approach has the potential to offer novel treatments for currently incurable diseases, addressing significant unmet medical needs.

Arrowhead Pharmaceuticals operates in a competitive landscape characterized by numerous biotechnology companies and pharmaceutical giants investing in RNA interference (RNAi) therapeutics. Key players in this field include Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, and Ionis Pharmaceuticals. These companies possess diverse RNAi platforms and pipelines targeting various diseases. Additionally, large pharmaceutical companies such as Roche, Novartis, and Pfizer have shown interest in RNAi technology through collaborations or licensing agreements. The competitive landscape is expected to intensify as more companies recognize the potential of RNAi therapeutics and invest in research and development.

Arrowhead Pharmaceuticals has demonstrated promising progress in its clinical trials. The company's lead product candidate, ARO-AAT, is being evaluated in Phase 3 trials for the treatment of alpha-1 antitrypsin (AAT) deficiency, a rare genetic disorder that can lead to liver and lung damage. Positive interim data from these trials have generated excitement within the industry and the patient community. Arrowhead also has several other candidates in earlier-stage clinical trials for conditions such as hepatitis B, cardiovascular disease, and neurological disorders. The company's robust pipeline and encouraging clinical results position it well for continued growth and potential commercial success.

To further strengthen its position in the market, Arrowhead Pharmaceuticals has forged strategic partnerships with leading pharmaceutical companies. In 2021, the company entered into a collaboration and licensing agreement with Janssen Biotech, a subsidiary of Johnson & Johnson, for the development and commercialization of RNAi therapeutics targeting multiple targets. This collaboration provides Arrowhead with access to Janssen's expertise and resources, potentially accelerating the development and commercialization of its product candidates. Such strategic partnerships are crucial for Arrowhead to expand its reach, access new markets, and enhance its overall competitiveness in the RNAi therapeutics landscape.

Future Outlook and Growth Opportunities

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical enterprise concentrated on developing remedies for hard-to-treat illnesses. Its robust pipeline contains therapeutics leveraging the RNA interference gadget to silence particular genes linked to illnesses and improving affected person outcomes. Arrowhead has a record of achievement in progressing its products via clinical improvement, partnering with industry leaders, and bringing treatments to patients in need.

Arrowhead has a strong pipeline of therapeutic candidates, with multiple programs in clinical development for a range of diseases. Its lead product candidate, ARO-AAT, is a treatment for alpha-1 antitrypsin deficiency, a rare genetic disease that can lead to liver and lung damage. ARO-AAT has demonstrated promising results in clinical trials, and Arrowhead is planning to file for regulatory approval in 2023. The company also has several other product candidates in clinical development for diseases such as hepatitis B, chronic kidney disease, and cancer.

Arrowhead has a strong track record of partnering with other pharmaceutical companies to develop and commercialize its products. The company has partnered with Janssen Pharmaceuticals, Takeda Pharmaceutical Company, and Boehringer Ingelheim to develop and commercialize its products. These partnerships provide Arrowhead with access to resources and expertise that it would not have on its own. It also helps to reduce the risk and cost of developing and commercializing its products.

Arrowhead is well-positioned for continued success. The company has a strong pipeline of therapeutic candidates, a history of successful partnerships, and a team of experienced scientists and managers. The company is also financially sound, with a strong cash position and access to capital. Investors are optimistic about Arrowhead's future prospects, and the company's stock price has been on a steady upward trend in recent years.

Operating Efficiency

Arrowhead Pharmaceuticals, also known as Arrowhead, has demonstrated steady improvement in its operating efficiency over the past several years. In 2021, the company's operating expenses decreased by 17% year-over-year, primarily due to a reduction in research and development (R&D) costs. This decline in R&D expenses was attributed to the completion of several clinical trials and the streamlining of Arrowhead's research programs.

Furthermore, Arrowhead has been successful in controlling its administrative and general expenses, which declined by 10% in 2021 compared to the previous year. This reduction was primarily driven by lower legal and professional fees, as well as a decrease in travel and entertainment expenses. As a result of these cost-cutting measures, Arrowhead's operating margin improved significantly in 2021, reaching 71%, compared to 58% in 2020.

Arrowhead's operating efficiency has also been reflected in its net income, which increased by 21% in 2021, reaching $123 million. This growth was primarily driven by an increase in collaboration revenue, which rose by 43% year-over-year. Additionally, Arrowhead's non-operating income, consisting mainly of interest income, also contributed to the company's improved net income.

Overall, Arrowhead Pharmaceuticals has made significant progress in enhancing its operating efficiency, leading to improved profitability and financial performance. The company's focus on cost control, coupled with its growing collaboration revenue, has positioned it well for continued success in the future.

Risk Assessment

Arrowhead Pharmaceuticals Inc. (Arrowhead) operates as a clinical-stage biopharmaceutical company. The company focuses on developing medicines to treat intractable diseases by silencing the genes that cause them. Arrowhead's pipeline includes RNA interference (RNAi) therapeutics targeting a range of diseases, including hepatitis B virus (HBV), chronic kidney disease (CKD), and cancer.

Arrowhead faces several risks associated with its operations and industry. Clinical Development and Regulatory Approval Risk: The success of Arrowhead's business depends on the successful development and regulatory approval of its product candidates. Clinical trials are complex and time-consuming, and there is no guarantee that Arrowhead's product candidates will be safe and effective or that they will be approved by regulatory authorities. Intellectual Property Risk: Arrowhead's business depends on its intellectual property (IP) rights, including patents and trade secrets. If Arrowhead's IP rights are challenged or invalidated, it could significantly harm its business.

Manufacturing and Supply Chain Risk: Arrowhead's business depends on its ability to manufacture and supply its product candidates. If Arrowhead experiences problems with its manufacturing or supply chain, it could disrupt its business and harm its reputation.

Competition Risk: Arrowhead faces competition from other companies developing RNAi therapeutics and other treatments for the diseases it targets. If competitors' products are more effective, safer, or less expensive than Arrowhead's products, it could harm Arrowhead's business.


  1. P. Marbach. Simulated-Based Methods for Markov Decision Processes. PhD thesis, Massachusetts Institute of Technology, 1998
  2. N. B ̈auerle and J. Ott. Markov decision processes with average-value-at-risk criteria. Mathematical Methods of Operations Research, 74(3):361–379, 2011
  3. G. Shani, R. Brafman, and D. Heckerman. An MDP-based recommender system. In Proceedings of the Eigh- teenth conference on Uncertainty in artificial intelligence, pages 453–460. Morgan Kaufmann Publishers Inc., 2002
  4. Y. Le Tallec. Robust, risk-sensitive, and data-driven control of Markov decision processes. PhD thesis, Massachusetts Institute of Technology, 2007.
  5. N. B ̈auerle and J. Ott. Markov decision processes with average-value-at-risk criteria. Mathematical Methods of Operations Research, 74(3):361–379, 2011
  6. A. Shapiro, W. Tekaya, J. da Costa, and M. Soares. Risk neutral and risk averse stochastic dual dynamic programming method. European journal of operational research, 224(2):375–391, 2013
  7. Dudik M, Langford J, Li L. 2011. Doubly robust policy evaluation and learning. In Proceedings of the 28th International Conference on Machine Learning, pp. 1097–104. La Jolla, CA: Int. Mach. Learn. Soc.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.